Medtronic (NYSE:MDT) Issues FY 2026 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 5.500-5.600 for the period, compared to the consensus EPS estimate of 5.450. The company issued revenue guidance of -, compared to the consensus revenue estimate of $33.5 billion.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MDT. Mizuho cut their price objective on Medtronic from $100.00 to $98.00 and set an “outperform” rating on the stock in a research report on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a research report on Monday. Royal Bank of Canada cut their price objective on Medtronic from $105.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday. Truist Financial cut their price objective on Medtronic from $93.00 to $90.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Finally, Citigroup upgraded Medtronic from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $92.00 to $107.00 in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $96.07.

Medtronic Stock Down 4.1%

Medtronic stock opened at $80.93 on Friday. The stock has a market cap of $103.80 billion, a PE ratio of 24.60, a price-to-earnings-growth ratio of 2.22 and a beta of 0.81. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.39 and a current ratio of 1.90. Medtronic has a one year low of $75.96 and a one year high of $96.25. The stock has a fifty day moving average of $85.29 and a 200 day moving average of $86.50.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Wednesday, May 21st. The medical technology company reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.58 by $0.04. The company had revenue of $8.93 billion during the quarter, compared to analysts’ expectations of $8.81 billion. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. Medtronic’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.46 earnings per share. As a group, sell-side analysts predict that Medtronic will post 5.46 EPS for the current year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 11th. Investors of record on Friday, June 27th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 3.51%. The ex-dividend date is Friday, June 27th. This is a boost from Medtronic’s previous quarterly dividend of $0.70. Medtronic’s dividend payout ratio is 85.11%.

Institutional Trading of Medtronic

An institutional investor recently raised its position in Medtronic stock. Brighton Jones LLC grew its stake in Medtronic plc (NYSE:MDT) by 1,368.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,989 shares of the medical technology company’s stock after buying an additional 37,265 shares during the quarter. Brighton Jones LLC’s holdings in Medtronic were worth $3,194,000 as of its most recent SEC filing. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.